NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

痤瘡藥品市場:全球行業趨勢,佔有率,規模,增長,機會,預測(2020-2025年)

Acne Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025

出版商 IMARC Services Private Limited 商品編碼 960449
出版日期 內容資訊 英文 109 Pages
商品交期: 2-3個工作天內
價格
痤瘡藥品市場:全球行業趨勢,佔有率,規模,增長,機會,預測(2020-2025年) Acne Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025
出版日期: 2020年09月03日內容資訊: 英文 109 Pages
簡介

2014年至2019年,全球痤瘡藥物市場的複合年增長率約為5%。痤瘡藥物是用於治療以皮膚的毛囊發炎為特徵的皮膚感染的藥物。這通常是由於荷爾蒙失調,皮膚油膩,死皮細胞積聚,細菌,壓力,液體攝入不足以及糖,鹽或碳水化合物攝入過多而引起的。常用的痤瘡藥物包括抗生素,抗雄激素藥物,異維A酸以及局部藥物,例如類維生素A,水楊酸,基於壬二酸的軟膏和基於Dapson的凝膠。這些藥物可最大程度地減少體內油脂的產生,提高皮膚細胞的新陳代謝速度,抑製粉刺的形成,減少疤痕和對皮膚的損害,並預防炎症。

尋常痤瘡等與皮膚有關的疾病的流行是市場增長的主要驅動力之一。此外,公眾越來越意識到使用優質護膚產品的好處,這正在推動市場增長。有效和可能的副作用少的治療方法和替代治療方法的發展進一步推動了市場。

消費者越來越喜歡使用天然成分製成的產品的趨勢也成為增長的動力。因此,製造商正在開發將天然草藥和有機成分(例如蘆薈,綠茶,蜂蜜,荷荷巴油和迷迭香)注入體內的產品,以治療痤瘡。隨著提供針對用戶皮膚類型定制痤瘡藥物的在線零售平台的氾濫,消費者消費能力的提高也有望為市場帶來光明的前景。痤瘡藥物市場預計在未來五年將繼續溫和增長。

該報告調查了痤瘡藥物市場,並提供了市場概況,以及痤瘡類型,藥物類別,藥物類型,給藥途徑,地區和進入市場的公司概況的趨勢。

目錄

第1章序言

第2章範圍和調查方法

第3章執行摘要

第4章簡介

第5章全球痤瘡藥物市場

  • 市場概況
  • 市場表現
  • COVID-19的影響

第6章痤瘡類型的市場細分

  • 粉刺
  • 炎性
  • 囊性
  • 術後/傷口

第7章按藥品類別細分的市場

  • 類視黃醇
  • 抗生素
  • 激素
  • 伴隨藥物
  • 其他

第8章按藥品類型細分的市場

  • 非處方藥
  • 處方藥

第9章按管理途徑劃分的市場

  • 外用劑
  • 口服製劑
  • 注射

第10章按地區劃分的市場

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞
    • 印度尼西亞
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 意大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 國家細分市場

第11章SWOT分析

第12章價值鏈分析

第13章波特五力分析

第14章價格分析

第15章競爭情況

  • 市場結構
  • 關鍵公司
  • 關鍵公司資料
    • Allergan Plc
    • Bausch Health Companies Inc.
    • Bayer Aktiengesellschaft
    • Cipher Pharmaceuticals Inc.
    • Galderma Holding SA
    • Johnson & Johnson
    • Pfizer Inc.
    • Reckitt Benckiser Group Plc
    • Skinvisible Pharmaceuticals Inc.
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: SR1019L94_Report

The global acne drugs market grew at a CAGR of around 5% during 2014-2019. Acne drugs refer to the medications used for treating a dermatological infection characterized by the inflammation in the hair follicles on skin. It is usually caused by hormonal imbalance, oily skin, accumulation of dead skin cells, bacteria, stress, inadequate intake of water and excessive consumption of sugars, salts or carbohydrates. Some of the commonly used acne drugs include topical medications, such as retinoids, salicylic and azelaic acid-based ointments and dapsone-based gels, along with antibiotics, anti-androgen agents and isotretinoin. These drugs minimize the levels of oil production in the body, speed up skin cell turnover, control acne breakouts, reduce scarring and damage to the skin and prevent inflammation.

The increasing prevalence of skin-related diseases, such as acne vulgaris, is one of the key factors driving the growth of the market. Moreover, rising awareness among the masses regarding the benefits of using premium skin care products is driving the market growth. The market is further being driven by the development of effective therapeutics and treatment alternatives with reduced side effects and high potential. Increasing consumer preference for products manufactured using natural ingredients is acting as another growth-inducing factor. Manufacturers are, therefore, developing products infused with natural herbs and organic ingredients, such as aloe vera, green tea, honey, jojoba oil and rosemary, for treating acne. Other factors, including rising expenditure capacities of consumers, along with the proliferation of online retail platforms that offer customized acne drugs according to the user's skin type, are expected to create a positive outlook for the market. Looking forward, IMARC Group expects the global acne drugs market to continue its moderate growth during the next five years.

Breakup by Acne Type:

  • Comedonal
  • Inflammatory
  • Cystic
  • Postsurgical/Wound

Breakup by Drug Class:

  • Retinoids
  • Antibiotics
  • Hormonal Agents
  • Combination Drugs
  • Others

Breakup by Drug Type:

  • OTC Drugs
  • Prescription Drugs

Breakup by Route of Administration:

  • Topical
  • Oral
  • Injectable

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

  • The report has also analysed the competitive landscape of the market with some of the key players being Allergan Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, Cipher Pharmaceuticals Inc., Galderma Holding SA, Johnson & Johnson, Pfizer Inc., Reckitt Benckiser Group Plc, Skinvisible Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global acne drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global acne drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the acne type?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global acne drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Acne Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Acne Type

  • 6.1 Comedonal
    • 6.1.1 Market Trends
    • 6.1.3 Market Forecast
  • 6.2 Inflammatory
    • 6.2.1 Market Trends
    • 6.2.3 Market Forecast
  • 6.3 Cystic
    • 6.3.1 Market Trends
    • 6.3.3 Market Forecast
  • 6.4 Postsurgical/Wound
    • 6.4.1 Market Trends
    • 6.4.3 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Retinoids
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Antibiotics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Hormonal Agents
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Combination Drugs
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 OTC Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Prescription Drugs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Topical
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Oral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Injectable
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Allergan Plc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bausch Health Companies Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Bayer Aktiengesellschaft
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Cipher Pharmaceuticals Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Galderma Holding SA
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Pfizer Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Reckitt Benckiser Group Plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Skinvisible Pharmaceuticals Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Sun Pharmaceutical Industries Limited
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Teva Pharmaceutical Industries Ltd.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis